1
|
Wang S, Haikarainen A, Pohjakallio A, Sipilä J, Kaskinoro J, Juhila S, Jalava N, Koskinen M, Vesajoki M, Kumpulainen E, Pystynen J, Koskelainen T, Holm P, Din Belle D. Development of Benzodioxine-heteroarylpiperazines as Highly Potent and Selective α2c Antagonists. Bioorg Med Chem Lett 2022; 77:129005. [PMID: 36174834 DOI: 10.1016/j.bmcl.2022.129005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 09/21/2022] [Accepted: 09/22/2022] [Indexed: 11/02/2022]
Abstract
Here is reported the design and synthesis of a series of highly potent and selective α2C antagonists using benzodioxine methyl piperazine as a central scaffold by pharmacophoric analysis to improve the pharmacokinetics of suboptimal clinical candidate molecules.
Collapse
Affiliation(s)
- Shouming Wang
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland.
| | - Anssi Haikarainen
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Antti Pohjakallio
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Julius Sipilä
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Janne Kaskinoro
- Department of DMPK & Safety Science, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Satu Juhila
- Department of DMPK & Safety Science, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Niina Jalava
- Department of CNS Research, Orion Corporation Orion Pharma, Tengströminkatu 8, 20360, Turku, Finland
| | - Mikko Koskinen
- Department of DMPK & Safety Science, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Marja Vesajoki
- Department of Biology, Orion Corporation Orion Pharma, Tengströminkatu 8, 20360, Turku, Finland
| | - Esa Kumpulainen
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Jarmo Pystynen
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Tuula Koskelainen
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - Patrik Holm
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| | - David Din Belle
- Department of Medicinal Chemistry, Orion Corporation Orion Pharma, Orionintie 1, PL 65, FI-02101, Finland
| |
Collapse
|
2
|
Alluri S, Eisenberg SM, Grisanti LA, Tanner M, Volkow ND, Kim SW, Kil KE. Preclinical evaluation of new C-11 labeled benzo-1,4-dioxane PET radiotracers for brain α2C adrenergic receptors. Eur J Med Chem 2022; 243:114764. [DOI: 10.1016/j.ejmech.2022.114764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 09/04/2022] [Accepted: 09/07/2022] [Indexed: 11/24/2022]
|
4
|
Kapsa S, Thuss U, Boxnick S, Schaumann F, Schultz A, Unger S, Otto C. Pharmacokinetics, Safety, and Tolerability of the α 2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects. Clin Pharmacol Drug Dev 2021; 11:296-308. [PMID: 34464517 DOI: 10.1002/cpdd.1018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 08/03/2021] [Indexed: 11/08/2022]
Abstract
The α2C -adrenoreceptor antagonist BAY 1193397 is in development for the oral treatment of diabetic foot ulcers. Safety, tolerability, and pharmacokinetics of BAY 1193397 were investigated in 3 randomized, single-center phase 1 studies in healthy male subjects: a first-in-human study (single oral doses of 0.5-50 mg), a relative bioavailability and food effect study (single doses of 1 and 10 mg), and a multiple-dose escalation study (using 2 and 5 mg twice daily and 10 and 20 mg once daily for 9 consecutive days). BAY 1193397 was rapidly absorbed in the fasted state, peak concentrations were reached between 0.6 and 2 hours. The mean terminal half-life was in the range of 17 to 20 hours. Area under the plasma concentration-time curve and maximum concentration appeared to be dose proportional, with a negligible food effect. There were no high-accumulation effects of BAY 1193397 after repeated dosing. BAY 1193397 was safe and well tolerated. At supratherapeutic plasma concentrations, there were slight transient increases in norepinephrine levels, heart rate, and blood pressure that were more pronounced after a single dose compared to steady state and appeared to be maximum concentration dependent. The results of the presented studies support the conduct of subsequent clinical trials with BAY 1193397 in patients with diabetes and compromised microcirculation.
Collapse
Affiliation(s)
| | - Uwe Thuss
- Bioanalytics, BAYER AG, Wuppertal, Germany
| | - Stefanie Boxnick
- CRS Clinical Research Services, Wuppertal GmbH, Wuppertal, Germany
| | - Frank Schaumann
- CRS Clinical Research Services, Wuppertal GmbH, Wuppertal, Germany
| | - Armin Schultz
- CRS Clinical Research Services, Mannheim GmbH, Mannheim, Germany
| | - Sigrun Unger
- Research and Early Development Statistics, BAYER AG, Wuppertal, Germany
| | - Christiane Otto
- Clinical Experimentation Cardiovascular, BAYER AG, Wuppertal, Germany
| |
Collapse
|